Therapeutic Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate versus Budesonide and Tiotropium Dihydrate in Managing COPD Exacerbations, Lung Function, Symptoms, and Quality of Life
Main Article Content
Keywords
COPD, Budesonide/Glycopyrronium/Formoterol Fumarate, Budesonide and Tiotropium Dihydrate, Multicenter Study, Therapeutic Efficacy, Lung Function, Symptoms, Quality of Life.
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) poses a substantial global health burden,necessitating effective therapeutic interventions. This study undertakes a comparative analysis of the therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) against Budesonide and Tiotropium Dihydrate (BUD/TIO) in addressing COPD exacerbations, lung function, symptoms, and overall quality of life
References
Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease.
Annals of Pharmacotherapy. 2022 May;56(5):582-91.
2. Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of
COPD. Expert Review of Clinical Pharmacology. 2020 Aug 2;13(8):865-74.
3. Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M,
Sharma R, Compton C, Vogelmeier CF. Fluticasone furoate/umeclidinium/vilanterol
(FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network
meta-analysis. Advances in Therapy. 2022 Sep;39(9):3957-78.
4. Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Efficacy
and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in
Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Respiratory Medicine. 2023 Nov 1;218:107393.
5. Li A, Chan HP, Gan PX, Liew MF, Wong WF, Lim HF. Eosinophilic endotype of chronic
obstructive pulmonary disease: similarities and differences from asthma. The Korean Journal of
Internal Medicine. 2021 Nov;36(6):1305.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.